|
advertisement
|
|
|
|
| Healthcare IT and Biotechnology News Release |
| News Home :: Healthcare IT and Biotechnology News Releases :: More News Releases on this day |
| Date of Publication: Wednesday, July 06, 2011 |
New Genedata Biologics Advances Open Innovation in Biopharmaceutical Research |
| First-in-Class Biologics Data Management Platform Now Enables Biopharmaceutical R&D Collaboration and Technology Transfers |
Basel, Switzerland -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™ 1.5, the latest version of its enterprise solution for biologics R&D. The new Genedata Biologics provides support for cross-departmental and external data exchange as well as technology transfers among research partners, such as pharmaceutical and biotech companies, technology providers, contract research organizations (CROs), and academic research networks. Genedata Biologics was specifically designed to support Open Innovation models.
Genedata Biologics is a first-in-class, off-the-shelf software solution for integrated data management and analysis of biologics R&D activities. It streamlines and automates the biologics lead generation and optimization process, including antibody screening, protein engineering, and protein production. These capabilities enable pharmaceutical and biotechnology R&D organizations to more efficiently discover and develop novel protein-based therapies.
Open Innovation Support
Supporting Open Innovation models, Genedata Biologics 1.5 simplifies data exchange by providing a collaboration platform for pharmaceutical, biotechnology, and technology companies, CROs, and academic networks. The platform now facilitates the exchange of raw and result data with standardized data exchange formats for molecule data, sequence data, assay data, and other relevant data types. As an integrated data management platform, Genedata Biologics enables registration and documentation of externally-generated materials and samples such as proteins, DNA and cell lines, including antigen materials, plasmid batches, and antibody libraries.
Genedata Biologics also provides the infrastructure for rapid implementation of corporate-specific workflows and technologies such as proprietary molecule formats, proprietary antibody libraries and display systems, or corporate identifiers. This capability will enable technology providers to easily transfer their technology within partner networks.
"Genedata focuses on providing a complete biologics platform that covers the full R&D process from antibody screening to protein engineering and production," said Dr. Othmar Pfannes, CEO of Genedata. "The latest release of Genedata Biologics is an important milestone in realizing that strategic goal, which promotes adoption of new collaboration models based on technology transfer, division-of-labor, and technology in-licensing," continued Pfannes. "Genedata Biologics underscores our commitment to and investments in biopharma manufacturing and emerging biosimilars markets."
|
|
| Other News Items Published on the Wednesday, July 06, 2011 |
|
|